Trending

video

The implosion of Lehman Brothers was just two years ago and yet Wall Street and the financial industry are still struggling to rebuild from the ashes. But as the economy recovers, are bank stocks good buys? Here are the bull and bear cases for three of the nation's biggest banks.

Stocks closed higher Friday for the seventh time in the last eight sessions, helped by a stronger-than-expected reading on wholesale inventories and sales. Volume was especially light at the end of the holiday shortened trading week but September's mini-rally continued nonetheless.

Not too long ago, Research In Motion, Nokia and Motorola each enjoyed the sort of market-dominating mojo that Apple and Google boast today. But all three have slipped badly and their shares have tanked. The question now, is whether these companies can regain lost ground and if their fallen stocks are now good values.

The Los Angeles Times reports that Blockbuster has been meeting with senior debt holders and Hollywood studios to discuss a Chapter 11 filing in mid-September -- a path that would likely result in more store closures.

Dole Food Company is public again but investors haven't been paying much attention to the green produce producer. Hilary Kramer says that maybe they should and she explains why investors, like her, may soon go bananas over this green company.

Nobody should ever consider owning a home. One of the biggest scams perpetrated on the American public is that owning a home is the "American Dream." It's more nightmare than dream as now millions of Americans know. But it has always been that way. Here's why.

Hilary Kramer recently recommended shares of Jazz Pharmaceuticals, which surged 16% on Wednesday before closing up just 3%. The reason: The U.S. Food and Drug Administration approved the drug, used for narcolepsy, for fibromyalgia.Kramer also recommends two other biotech medical equipment companies with upside potential.

As the stock market falls, it may seem difficult to find stocks that will do well. But Hilary Kramer, who focuses on under the radar, game changing stocks, says there are some great opportunities among biotech and medical equipment companies.

Tech stocks are on sale these days, giving buyers a chance to pick up shares at impressive discounts. The sale isn't due entirely to market jitters. A good sex scandal helped to create opportunity as did less than rosy earnings forecasts.

Earnings season gave a lift to stocks, but now the market is focused again on the global economy and U.S. macroeconomic issues. FBN Securities' Cort Gwon says that even in a market like this one that's stuck in a trading range, investors can find ways to profit.

The bear came back with a roar this week. Just a week earlier, better-than-expected corporate earnings sent stocks soaring. But this week, renewed worries from the Fed about the U.S. economic recovery led the forces pushing stocks down about 375 points over a three-day period.

Stocks were surprisingly resilient after the lousy July jobs report was released on Friday. Now, with the report behind us and earnings season just about over, what will drive the market in the week ahead?

Stocks were doing just fine for most of the week only to get clobbered by a dismal July jobs report released on Friday that sent shivers through the market. Despite some good news during the week, the jobs report provides evidence that the economy is not rebounding as quickly as hoped.

Michael Feder of Radar Logic thinks it does. And he adds that government, which has underwritten or guaranteed almost every new mortgage since the financial crisis began, is in a precarious position itself. But Feder offers one possible solution.

The third peak week of earnings season is here. But if stocks have any hope of breaking out of their range-bound rut, the market will need proof of a consistent drop in weekly jobless claims, says Kenny Polcari, managing director at interdealer broker ICAP Corporates.

Chances are, every day you use products from Colgate-Palmolive, Clorox and Kellogg. These consumer staple companies have solid balance sheets and their shares offer investors a reliable stream of dividends. But are their stocks attractive? Will you still buy Glad trash bags and Colgate toothpaste if deflation hits the economy? DailyFinance's Nikhil Hutheesing and Dan Burrows face-off on the companies, the stocks, and whether they should be in your portfolio.

With mortgage rates at all time lows, you would think these would be good times for the housing market. But Michael Feder of Radar Logic says that the housing market is fragile, exhibiting signs of strain.

With the stock market showing resilience recently, it appears that investors have forgotten about the threat of deflation. In this video interview, well-known market bear Gary Shilling warns that deflation is coming, and tells you what to invest in to ride it out -- and what to avoid.

With the price of gold now off its highs, should investors put money into the precious metal? James Altucher explains why there are better places to invest in this short and frank discussion on silver, gold and stocks.

Economist Gary Shilling warns that turbulent times remain ahead for the Eurozone and the future of the Euro as a currency. He says the close financial links between the European countries of the north and south will lead to further financial chaos.

They have some of the best-known brands in the world, growth opportunities in emerging markets and do a solid job returning cash to shareholders though dividends and buybacks -- but not all big beverage company stocks are created equal.

Formula Capital's James Altucher says that there has never been a better time to pick up high-quality stocks at bargain prices -- as long as you choose the right ones. Altucher recommends three "beaten over the head with a bat" stocks he expects will double in the next one to two years.

Despite efforts by the Federal Reserve, economist Gary Shilling says that deflation is about to hit the U.S. economy and that it could last for a decade. While there are plenty of economists who would disagree, Gary Shilling makes a persuasive argument and investors would do well to listen.